Targovax logoTargovax logo

  • About
    About
    Close
      • About Targovax
      • Management Team
      • Board of Directors
      • Careers
  • Technology
    Technology
    Close
      • ONCOS – Oncolyctic Virus
      • Intellectual Property Rights
      • Publications
  • Pipeline
    Pipeline
    Close
      • Our pipeline
      • Development Program
        • Melanoma
        • Mesothelioma
        • Next generation viruses
  • Partnering
  • Investors & Media
    Investors & Media
    Close
      • Our strategy
      • Press releases
      • Financial Reports
      • Presentations
      • Prospectus
      • Debt
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Events
      • Contact
      • Subscribe
  • Governance
    Governance
    Close
      • Corporate Governance Policy
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
        • General Meetings
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Articles of Association
  • Contacts
    Contacts
    Close
      • Offices
      • Investors & Media
    • About
      • About Targovax
      • Management Team
      • Board of Directors
      • Collaborations
      • Careers
    • Technology
      • ONCOS – Oncolyctic Virus
      • Intellectual Property Rights
      • Publications
    • Pipeline
      • Our pipeline
      • Development program
    • Partnering
      • TG Mutant RAS neoantigen vaccine – Available for partnering
    • Investors & Media
      • Our strategy
      • Share information
        • Share facts
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Financial Reports
      • Press releases
      • Presentations
      • Prospectus
      • Debt
      • Events
      • Subscribe
      • Contact
    • Governance
      • Corporate Governance Report
      • Corporate Social Responsibility Principles
      • About General Meeting
        • General Meetings
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Articles of Association
    • Contacts
      • Offices
      • Investors & Media

    Financial Reports
    Share price
    Share price
    2016
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2015
    • 2014
    • All years
    Interim Reports
    • Annual Reports
    • All types
      Report Presentation Webcast ESEF ESEF (view XBRL)
    April 25, 2017 Q1 First Quarter
    February 16, 2017 Q4 Fourth Quarter
    November 17, 2016 Q3 Third Quarter
    August 25, 2016 Q2 Second Quarter
    May 12, 2016 Q1 First Quarter
    IR contact
    Dr Lubor Gaal
    Dr Lubor Gaal
    Chief Financial Officer
    lubor.gaal@targovax.com
    (+34) 683 343 811
    Renate Birkeli
    Renate Birkeli
    Investor Relations
    renate.birkeli@targovax.com
    (+47) 922 61 624

    Q3 interim report 2022

    Targovax ASA (OSE: TRVX) announced its third quarter 2022 results on Thursday 3 November 2022. Targovax’s management will present the results at a live streamed webcast at 10:00 am CET to investors, analysts and the press. 

    • Report
    • Presentation
    • Webcast
    Read the report

    Subscribe

    Read more about our Protection of your personal data.
    • PRINT
    • STAY CONNECTED
    • Cookies
    • Privacy policy